The Company reported net income for the nine months ended September 30, 2007, of $7.9 million, or $0.14 per fully diluted share, compared with a net loss of $10.2 million, or $0.19 per fully diluted share, for the same prior year period. Included in net income for the nine months ended September 30, 2007, is a gain on sale of products of $27.7 million offset in part by a non- cash operating charge relating to acquired in-process research and development of approximately $10.0 million, a non-cash charge of $3.2 million for stock- based compensation expense and an income tax provision of $236,000 resulting primarily from the anticipated tax impact of recognizing the various milestone payments received from the sale of certain non-core assets to third parties. Included in the net loss for the nine months ended September 30, 2006, is a non-cash gain for a change in valuation of derivatives of $1.3 million. There was no similar non-cash gain during 2007 since the related derivatives expired at the end of 2006.
As of September 30, 2007, the Company had approximately $87.5 million in unrestricted cash, cash equivalents and marketable securities.
Corporate News
July 2007:
-- The Company announced that investigators at The Translational
Genomics Research Institute (TGen) and TGen Clinical Research
Services (TCRS) at Scottsdale Healthcare in Scottsdale, Arizona, have
dosed the first patient
'/>"/>
| SOURCE SuperGen Inc. Copyright©2007 PR Newswire. All rights reserved |